BRAF Mutations in Iranian Patients with Papillary Thyroid Carcinoma |
Ranjbari, Nastran
(Department of Pathology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences)
Almasi, Sara (Department of Pathology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences) Mohammadi-asl, Javad (Medical Genetics Department, Ahvaz Jundishapur University of Medical Sciences) Rahim, Fakher (Toxicology Research Center, Ahvaz Jundishapur University of Medical Sciences) |
1 | Avruch J, Khokhlatchev A, Kyriakis JM, et al (2001). Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog Horm Res, 56, 127-55. DOI |
2 | Davies H, Bignell GR, Cox C, et al (2002). Mutations of the BRAF gene in human cancer. Nature, 417, 949-54. DOI ScienceOn |
3 | Dralle H, Machens A (2008). Surgical approaches in thyroid cancer and lymph-node metastases. Best Pract Res Clin Endocrinol Metab, 22, 971-87. DOI ScienceOn |
4 | Durante C, Puxeddu E, Ferretti E, et al (2007). BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab, 92, 2840-3. DOI |
5 | Jeong D, Jeong Y, Lee S, et al (2012). Detection of BRAF(V600E) mutations in papillary thyroid carcinomas by peptide nucleic acid clamp real-time PCR: a comparison with direct sequencing. Korean J Pathol, 46, 61-67. DOI ScienceOn |
6 | Kim KH, Kang DW, Kim SH, Seong IO, Kang DY (2004). Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J, 45, 818-21. DOI ScienceOn |
7 | Kimura ET, Nikiforova MN, Zhu Z, et al (2003). High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res, 63, 1454-7. |
8 | Lalami Y, Awada A (2011). Recurrent thyroid cancer: a molecular-based therapeutic breakthrough. Curr Opin Oncol. 23, 235-40. DOI ScienceOn |
9 | Li X, Abdel-Mageed AB, Kandil E (2012). BRAF mutation in papillary thyroid carcinoma. Int J Clin Exp Med, 5, 310-5. |
10 | Mercer KE, Pritchard CA (2003). Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta, 1653, 25-40. |
11 | Meyerhardt JA, Mayer RJ (2005). Systemic therapy for colorectal cancer. N Engl J Med, 352, 476-487. DOI ScienceOn |
12 | Pakneshan S, Salajegheh A, Smith RA, Lam AK (2013). Clinicopathological relevance of BRAF mutations in human cancer. Pathology 2013 Apr 16 [PMID: 23594689]. |
13 | Peyssonnaux C, Eychene A (2001). The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell, 93, 53-62. DOI ScienceOn |
14 | Sithanandam G, Druck T, Cannizzaro LA, et al (1992). B-raf and a B-raf pseudogene are located on 7q in man. Oncogene, 7, 795-9. |
15 | Sithanandam G, Kolch W, Duh FM, Rapp UR (1990). Complete coding sequence of a human B-raf cDNA and detection of B-raf protein kinase with isozyme specific antibodies. Oncogene, 5, 1775-80. |
16 | Soares P, Trovisco V, Rocha AS, et al (2003). BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene, 22, 4578-80. DOI ScienceOn |
17 | Takahashi K, Eguchi H, Arihiro K, et al (2007). The presence of BRAF point mutation in adult papillary thyroid carcinomas from atomic bomb survivors correlates with radiation dose. Mol Carcinog, 46, 242-8. DOI ScienceOn |
18 | Xing MW, Tufano WH, Cohen RP, et al (2005). BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab, 90, 6373-9. DOI ScienceOn |
19 | Yoon JH, Kim EK, Moon HJ, Kwak JY (2013) Is follow-up BRAF (V600E) mutation analysis helpful in the differential diagnosis of thyroid nodules with negative results on initial analysis? PLoS One, 8, 58592. DOI |
20 | Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA (2003). High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res, 63, 4561-7. |